Forest Laboratories and CypressBioscience received FDA approval for Savella (milnacipran HCl), a selectiveserotonin and norepinephrine dual reuptake inhibitor (SNRI), for the managementof fibromyalgia.  In two Phase III clinical trials involving over 2,000 patientswith fibromyalgia, Savella demonstrated statistically significant and clinicallymeaningful concurrent improvements in pain, patient global assessment, andphysical function compared to placebo.

Savella is expected to beavailable in March 2009.

For more information call (800)678-1605 or visit www.frx.com.